Literature DB >> 28471540

In Vitro Antitumor Effects of AHR Ligands Aminoflavone (AFP 464) and Benzothiazole (5F 203) in Human Renal Carcinoma Cells.

Gabriela A Luzzani1, Mariana A Callero1,2, Anchala I Kuruppu3, Valentina Trapani4, Carolina Flumian1, Laura Todaro1,2, Tracey D Bradshaw3, Andrea I Loaiza Perez1,2.   

Abstract

We investigated activity and mechanism of action of two AhR ligand antitumor agents, AFP 464 and 5F 203 on human renal cancer cells, specifically examining their effects on cell cycle progression, apoptosis, and migration. TK-10, SN12C, Caki-1, and ACHN human renal cancer cell lines were treated with AFP 464 and 5F 203. We evaluated cytotoxicity by MTS assays, cell cycle arrest, and apoptosis by flow cytometry and corroborated a mechanism of action involving AhR signal transduction activation. Changes in migration properties by wound healing assays were investigated: 5F 203-sensitive cells show decreased migration after treatment, therefore, we measured c-Met phosphorylation by Western blot in these cells. A 5F 203 induced a decrease in cell viability which was more marked than AFP 464. This cytotoxicity was reduced after treatment with the AhR inhibitor α-NF for both compounds indicating AhR signaling activation plays a role in the mechanism of action. A 5F 203 is sequestered by TK-10 cells and induces CYP1A1 expression; 5F 203 potently inhibited migration of TK-10, Caki-1, and SN12C cells, and inhibited c-Met receptor phosphorylation in TK-10 cells. AhR ligand antitumor agents AFP 464 and 5F 203 represent potential new candidates for the treatment of renal cancer. A 5F 203 only inhibited migration of sensitive cells and c-Met receptor phosphorylation in TK-10 cells. c-Met receptor signal transduction is important in migration and metastasis. Therefore, we consider that 5F 203 offers potential for the treatment of metastatic renal carcinoma. J. Cell. Biochem. 118: 4526-4535, 2017.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  5F 203; AFP 464; AhR; HUMAN RENAL CANCER

Mesh:

Substances:

Year:  2017        PMID: 28471540     DOI: 10.1002/jcb.26114

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  4 in total

Review 1.  New Treatments in Renal Cancer: The AhR Ligands.

Authors:  Boris Itkin; Alastair Breen; Lyudmila Turyanska; Eduardo Omar Sandes; Tracey D Bradshaw; Andrea Irene Loaiza-Perez
Journal:  Int J Mol Sci       Date:  2020-05-18       Impact factor: 5.923

Review 2.  The Multifarious Link between Cytochrome P450s and Cancer.

Authors:  Abdullah M Alzahrani; Peramaiyan Rajendran
Journal:  Oxid Med Cell Longev       Date:  2020-01-03       Impact factor: 6.543

Review 3.  AhR and Cancer: From Gene Profiling to Targeted Therapy.

Authors:  Anaïs Paris; Nina Tardif; Marie-Dominique Galibert; Sébastien Corre
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

4.  A novel naphthalimide that selectively targets breast cancer via the arylhydrocarbon receptor pathway.

Authors:  J Gilbert; G N De Iuliis; A McCluskey; J A Sakoff
Journal:  Sci Rep       Date:  2020-08-19       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.